로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > LYPD3

LYPD3

요약

Name:Ly6/PLAUR domain-containing protein 3
Target Synonym:C4.4A,GPI-Anchored Metastasis-Associated Protein Homolog,2310061G07Rik,GPI-Anchored Metastasis-Associated Protein C4.4A Homolog,MIG-C4,UNQ491/PRO1007,Ly6/PLAUR domain-containing protein 3,LYPD3,Matrigel-Induced Gene C4 Protein,LY6/PLAUR Domain Containing 3
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 1 Clinical

제품 리스트 구매

제품 상태별:
제품 유형별 :
종별:
태그별:
결합물별:
제품번호 제품 설명 구조 순도 특징
LY3-H52H5 Human Human LYPD3 / C4.4A Protein, His Tag
LY3-H52H5-structure
LY3-H52H5-sds

일부의 생물활성 데이터

LY3-H52H5-MALS-HPLC
 LYPD3 ELISA

Immobilized Human LYPD3, His Tag (Cat. No. LY3-H52H5) at 1 μg/mL (100 μL/well) can bind various dilution ratio of Anti-LYPD3 Antibody (Rabbit Mab) (QC tested).

Synonym Name

LYPD3,MIG-C4,C4.4A

Background

Ly6/PLAUR domain-containing protein 3 (LYPD3) is also known as MIG-C4 ,C4.4A, GPI-anchored metastasis-associated protein C4.4A homolog and Matrigel-induced gene C4 protein,which is a cell membrane protein containing two UPAR/Ly6 domains. LYPD3 is expressed in placenta, skin and urothelium. LYPD3 is found in the majority of primary and metastatic transitional cell carcinomas (TCCs) and as well in breast cancer tissues, but not in adjacent normal tissues. LYPD3 play a role in supporting cell migration and it is not only probably involved in urothelial cell-matrix interactions, but also in tumor progression.

Clinical and Translational Updates

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Lupartumab amadotin BAY-1129980 Phase 1 Clinical Bayer AG Neoplasms Details
Lupartumab amadotin BAY-1129980 Phase 1 Clinical Bayer AG Neoplasms Details

This web search service is supported by Google Inc.

totop